Generated by All in One SEO v4.9.10, this is an llms.txt file, used by LLMs to index the site.

# Amydis

## Sitemaps

- [XML Sitemap](https://amydis.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Media](https://amydis.com/mediaold/) - Take a look at the different blogs and press releases written about Amydis and our Retinal Tracers.
- [Inside Amydis Strategy to Transform Neurodegenerative Disease Detection](https://amydis.com/2026/03/30/inside-amydis-strategy-to-transform-neurodegenerative-disease-detection/)
- [Amydis lands NIA funding to detect ALS in the eye](https://amydis.com/2026/03/11/amydis-lands-nia-funding-to-detect-als-in-the-eye/)
- [Amydis awarded $2.5M to develop diagnostic eye test for ALS](https://amydis.com/2026/03/16/amydis-awarded-2-5m-to-develop-diagnostic-eye-test-for-als/)
- [Amydis receives phase 2 NIH grant award of $2.5 million to advance a novel approach to detect biomarker TDP-43](https://amydis.com/2026/03/13/amydis-receives-phase-2-nih-grant-award-of-2-5-million-to-advance-a-novel-approach-to-detect-biomarker-tdp-43/)
- [Amydis Receives Phase 2 NIH Grant Award to Advance a Novel Approach to Detect Biomarker TDP-43](https://amydis.com/2026/03/13/amydis-receives-phase-2-nih-grant-award-to-advance-a-novel-approach-to-detect-biomarker-tdp-43/)
- [NIH Awards $2.5 Million to Advance Eye-Based Detection of ALS Biomarker TDP-43](https://amydis.com/2026/03/11/nih-awards-2-5-million-to-advance-eye-based-detection-of-als-biomarker-tdp-43/)
- [Seeing ALS Through the Eye: Amydis Receives Phase 2 NIH Grant Award to Advance a Novel Approach to Detect Biomarker TDP-43](https://amydis.com/2026/03/11/seeing-als-through-the-eye-amydis-receives-phase-2-nih-grant-award-to-advance-a-novel-approach-to-detect-biomarker-tdp-43/) - Seeing ALS Through the Eye: Amydis Receives Phase 2 NIH Grant Award to Advance a Novel Approach to Detect Biomarker TDP-43 SAN DIEGO, March 11, 2026 /PRNewswire/ — Amydis Inc., a privately held clinical-stage company pioneering a platform of ocular tracers that enable imaging of disease-related molecular biomarkers in the eye, announced today a Phase
- [Turning Sight into Insight: How Amydis Is Using the Retina to Rethink ALS Screening and Diagnostics ](https://amydis.com/2025/05/15/turning-sight-into-insight-how-amydis-is-using-the-retina-to-rethink-als-screening-and-diagnostics/)
- [Amydis to Present First Ocular Tracer Designed to Detect Transthyretin Amyloidosis (ATTR) at AAOOP Conference](https://amydis.com/2024/10/10/amydis-to-present-first-ocular-tracer-designed-to-detect-transthyretin-amyloidosis-attr-at-aaoop-conference/) - Amydis to Present First Ocular Tracer Designed to Detect Transthyretin Amyloidosis (ATTR) at AAOOP Conference SAN DIEGO, October 10, 2024 (GLOBE NEWSWIRE) – Amydis Inc., a privately held clinical-stage company pioneering a platform of ocular tracers that enable imaging of disease-related molecular biomarkers in the eye, announced today that Dr. Tatyana Milman, Professor of Ophthalmology
- [Detection of TTR Amyloid in the Conjunctiva Using a Novel Fluorescent Ocular Tracer](https://amydis.com/2024/02/18/detection-of-ttr-amyloid-in-the-conjunctiva-using-a-novel-fluorescent-ocular-tracer/) - Detection of TTR Amyloid in the Conjunctiva Using a Novel Fluorescent Ocular Tracer February 18, 2024 – Background: Transthyretin amyloidosis (ATTR) is a significant cause of cardiomyopathy and other morbidities in the elderly and Black Americans. ATTR can be treated with new disease-modifying therapies, but large shortfalls exist in its diagnosis. The objective of this
- [Amydis Receives NIH Grant Award to Develop a Novel TDP43 Retinal Tracer in Patients with ALS and FTD](https://amydis.com/2022/08/19/amydis-receives-nih-grant-award-to-develop-a-novel-tdp43-retinal-tracer-in-patients-with-als-and-ftd/) - Amydis Receives NIH Grant Award to Develop a Novel TDP43 Retinal Tracer in Patients with ALS and FTD San Diego, August 18, 2022 (GLOBE NEWSWIRE) – Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye, today announced a new Phase 1 grant
- [Amydis Diagnostics Awarded NIA-NIH Grant to Investigate Innovative Technology for Detection of Alzheimer's Disease](https://amydis.com/2015/09/29/amydis-diagnostics-awarded-nia-nih-grant-to-investigate-innovative-technology-for-detection-of-alzheimers-disease/) - Amydis Diagnostics Awarded NIA-NIH Grant to Investigate Innovative Technology for Detection of Alzheimer's Disease SAN DIEGO, Sept. 29, 2015 (GLOBE NEWSWIRE) — Amydis Diagnostics, Inc., a preclinical stage, privately-held pharmaceutical company developing proprietary chemistry and innovative approaches to detection of amyloidgenic protein-associated diseases, today announced a grant award by the National Institute of Aging (NIA),
- [Amydis Diagnostics Awarded NIH Grant to Further Investigate Innovative Technology for Early Detection of Alzheimer’s Disease](https://amydis.com/2017/03/19/amydis-diagnostics-awarded-nih-grant-to-further-investigate-innovative-technology-for-early-detection-of-alzheimers-disease/) - Amydis Diagnostics Awarded NIH Grant to Further Investigate Innovative Technology for Early Detection of Alzheimer’s Disease San Diego, CA, March 19, 2017: Amydis Diagnostics, Inc., a preclinical stage, privately-held pharmaceutical company developing proprietary chemistry and innovative approaches to detection of amyloid-related neurodegenerative disorders such as Alzheimer’s disease, announced that they received a Phase 2 SBIR
- [NIH Awards Cerebral Amyloid Angiopathy Grant to Amydis Diagnostics](https://amydis.com/2017/10/09/nih-awards-cerebral-amyloid-angiopathy-grant-to-amydis-diagnostics/) - NIH Awards Cerebral Amyloid Angiopathy Grant to Amydis Diagnostics San Diego, CA, October 9, 2017: Amydis Diagnostics, Inc., a privately-held pharmaceutical company developing proprietary chemistry and innovative approaches for the detection of amyloid-related diseases, announced today that they received a Phase 1 SBIR grant award from the National Institute on Aging of the National Institutes
- [Amydis Receives Parkinson’s Disease Grant from Michael J. Fox Foundation](https://amydis.com/2018/07/10/amydis-receives-parkinsons-disease-grant-from-michael-j-fox-foundation/) - Amydis Receives Parkinson’s Disease Grant from Michael J. Fox Foundation San Diego, CA, July 10, 2018: Amydis, Inc., a privately-held pharmaceutical company developing proprietary chemistry and innovative approaches for the detection of amyloid-related diseases, announced today that they received a grant award from The Michael J. Fox Foundation for Parkinson’s Research. Amydis will explore the
- [Amydis Awarded Prion Disease Grant from NIH](https://amydis.com/2018/09/26/amydis-awarded-prion-disease-grant-from-nih/) - Amydis Awarded Prion Disease Grant from NIH San Diego, CA, September 26, 2018: Amydis, Inc., a privately-held pharmaceutical company developing proprietary chemistry and innovative technology to detect amyloid-related diseases, announced today that they received a grant award from The National Institute of Health (NIH) to develop a novel diagnostic for prion disease. A prion, derived
- [Amydis Awarded NIH Ph2A Grant for Cerebral Amyloid Angiopathy](https://amydis.com/2019/09/23/amydis-awarded-nih-ph2a-grant-for-cerebral-amyloid-angiopathy/) - Amydis Awarded NIH Ph2A Grant for Cerebral Amyloid Angiopathy San Diego, CA, September 23, 2019: Amydis, Inc., a privately-held pharmaceutical company developing proprietary drugs to detect, monitor, and screen for amyloid-related diseases, announced today that they received a Phase 2A SBIR grant award from the National Institute on Aging of the National Institutes of Health
- [Amydis Awarded Michael J. Fox Foundation Grant to Accelerate Development of an Alpha-Synuclein Retinal Tracer to Diagnose Parkinson’s Disease Through the Eye](https://amydis.com/2020/08/11/amydis-awarded-michael-j-fox-foundation-grant-to-accelerate-development-of-an-alpha-synuclein-retinal-tracer-to-diagnose-parkinsons-disease-through-the-eye/) - Amydis Awarded Michael J. Fox Foundation Grant to Accelerate Development of an Alpha-Synuclein Retinal Tracer to Diagnose Parkinson’s Disease Through the Eye SAN DIEGO, Aug. 11, 2020 (GLOBE NEWSWIRE) — Amydis, Inc., a biotechnology company developing a new class of diagnostics to enable the early detection of neurological diseases through the retina, today announced that
- [Amydis Announces Successful Completion of a Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer Targeting TDP43 for the Diagnosis of ALS](https://amydis.com/2021/04/26/amydis-announces-successful-completion-of-a-pre-ind-meeting-with-the-fda-for-the-development-of-a-first-in-class-retinal-tracer-targeting-tdp43-for-the-diagnosis-of-als/) - Amydis Announces Successful Completion of a Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer Targeting TDP43 for the Diagnosis of ALS San Diego, December 6, 2021 (GLOBE NEWSWIRE) — Amydis Inc., a biotechnology company developing novel ocular contrast agents (“tracers”) targeting CNS biomarkers in the eye, today announced the successful
- [Amydis Announces Successful Completion of Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer for the Diagnosis of Alpha-synucleinopathies](https://amydis.com/2021/12/06/amydis-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-the-development-of-a-first-in-class-retinal-tracer-for-the-diagnosis-of-alpha-synucleinopathies/) - Amydis Announces Successful Completion of Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer for the Diagnosis of Alpha-synucleinopathies San Diego, April 26, 2021 (GLOBE NEWSWIRE) — Amydis Inc., a leading ocular tracer biotechnology company with a broad portfolio of diagnostic candidates for detection of neurodegenerative diseases in the eye, today
- [Amydis Receives $3 Million NIH Commercialization Readiness Pilot Grant Award for Novel Amyloid Beta Retinal Tracer in Cerebral Amyloid Angiopathy](https://amydis.com/2021/10/11/amydis-receives-3-million-nih-commercialization-readiness-pilot-grant-award-for-novel-amyloid-beta-retinal-tracer-in-cerebral-amyloid-angiopathy/) - Amydis Receives $3 Million NIH Commercialization Readiness Pilot Grant Award for Novel Amyloid Beta Retinal Tracer in Cerebral Amyloid Angiopathy SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) — Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye, today announced an award of
- [Amydis Receives NIH Grant Award to Develop a Novel Tau Retinal Tracer for Alzheimer’s Diseases and other Tauopathies](https://amydis.com/2021/09/02/amydis-receives-nih-grant-award-to-develop-a-novel-tau-retinal-tracer-for-alzheimers-diseases-and-other-tauopathies/) - Amydis Receives NIH Grant Award to Develop a Novel Tau Retinal Tracer for Alzheimer’s Diseases and other Tauopathies San Diego, September 2, 2021 (GLOBE NEWSWIRE) — Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye, today announced a new Phase 1 grant
- [Amydis Appoints Dr. Robert N. Weinreb as First Chair of Scientific Advisory Board](https://amydis.com/2022/03/29/amydis-appoints-dr-robert-n-weinreb-as-first-chair-of-scientific-advisory-board/) - Amydis Appoints Dr. Robert N. Weinreb as First Chair of Scientific Advisory Board San Diego, CA, March 29, 2022: Amydis Inc., a healthcare company developing a new class of molecular retinal diagnostics and digital biomarkers to accelerate the early detection and monitoring of neurodegenerative diseases, today announced the appointment of internationally recognized clinician scientist, Robert
- [Amydis Awarded Third Grant From The Michael J. Fox Foundation To Support First-In-Human Study Of A Retinal Tracer For Parkinson’s Disease](https://amydis.com/2022/10/27/amydis-awarded-third-grant-from-the-michael-j-fox-foundation-to-support-first-in-human-study-of-a-retinal-tracer-for-parkinsons-disease/) - Amydis Awarded Third Grant From The Michael J. Fox Foundation To Support First-In-Human Study Of A Retinal Tracer For Parkinson’s Disease San Diego, October 27, 2022 (GLOBE NEWSWIRE) – Amydis Inc., a privately held clinical-stage company pioneering a platform of diagnostic drug candidates targeting molecular biomarkers in the eye, today announced it has been awarded
- [Amydis Announces Enrollment of Cerebral Amyloid Angiopathy Participants in Phase 1/2a Retinal Tracer Trial](https://amydis.com/2023/02/21/amydis-announces-enrollment-of-cerebral-amyloid-angiopathy-participants-in-phase-1-2a-retinal-tracer-trial/) - Amydis Announces Enrollment of Cerebral Amyloid Angiopathy Participants in Phase 1/2a Retinal Tracer Trial February 21, 2023 (GLOBE NEWSWIRE) – Amydis Inc., a privately held clinical-stage company pioneering a platform of ocular tracers that enable imaging of disease biomarkers in the eye, today announced initiation of enrollment of patients with cerebral amyloid angiopathy (CAA), an
- [Amydis Launches Phase 2 Glaucoma Clinical Program Using Novel Retinal Tracer to Detect Amyloid Beta](https://amydis.com/2023/11/02/amydis-launches-phase-2-glaucoma-clinical-program-using-novel-retinal-tracer-to-detect-amyloid-beta/) - Amydis Launches Phase 2 Glaucoma Clinical Program Using Novel Retinal Tracer to Detect Amyloid Beta San Diego, November 2, 2023 – Amydis Inc., a privately held clinical-stage company pioneering a platform of ocular tracers to enable imaging of disease biomarkers in the eye, today announced it has launched a Phase 2 clinical program for its novel retinal
- [Amydis Unveils Phase 2 Clinical Trial for Glaucoma Detection Technology](https://amydis.com/2023/11/08/amydis-unveils-phase-2-clinical-trial-for-glaucoma-detection-technology/) - Amydis unveils Phase 2 clinical trial for Glaucoma detection technology November 8, 2023 (Ophthalmology Times) – Amydis Inc announced it has launched a Phase 2 clinical program for its novel retinal tracer, AMDX-2011P, to detect amyloid-beta in glaucoma patients.According to the company, AMDX-2011P, is a small molecule designed to enable detection and quantification of amyloid-beta deposits in
- [Amydis Receives $3.4 million NIH Commercialization Readiness Pilot Grant Award to Map Heterogeneity of Alzheimer’s Diseases in Human Clinical Trial](https://amydis.com/2023/11/14/amydis-receives-3-4-million-nih-commercialization-readiness-pilot-grant-award-tomap-heterogeneity-of-alzheimers-diseases-in-human-clinical-trial/) - Amydis Receives $3.4 million NIH Commercialization Readiness Pilot Grant Award to Map Heterogeneity of Alzheimer’s Diseases in Human Clinical Trial Using Novel Retinal Tracer Amydis Novel Tracer Utilizes an Affordable, Accessible, Non-Invasive Approach as part of a Standard Office Visit SAN DIEGO, Calif. (November 14, 2023) – Amydis Inc., a privately held clinical-stage company pioneering
- [Amydis Nabs $3.4M NIH Grant to Develop Retinal Biomarkers for Alzheimer's](https://amydis.com/2023/11/14/amydis-nabs-3-4m-nih-grant-to-develop-retinal-biomarkers-for-alzheimers/) - Amydis Nabs $3.4M NIH Grant to Develop Retinal Biomarkers for Alzheimer's November 14, 2023 (Percision Medicine Online) – NEW YORK – Amydis on Tuesday said it has received a two-year, $3.4 million grant from the US National Institutes of Health to fund the use of fluorescent tracers to develop a database of retinal biomarkers for Alzheimer’s
- [Ex-NFL Star Gary Plummer Supports Amydis Mission: "This is a Game Changer"](https://amydis.com/2024/01/26/ex-49ers-linebacker-gary-plummer-shares-his-early-onset-dementia-battle/) - Ex-NFL Star Gary Plummer Supports Amydis Mission: "This is a Game Changer" January 22, 2024 – Gary Plummer is a former professional football player who was a linebacker in the National Football League (NFL) and the United States Football League (USFL) and a Super Bowl champion. He signed with the San Diego Chargers in 1986
- [Amydis Awarded $3 Million NIH Grant to Explore Novel Alpha Synuclein Retinal Tracer in Non-human Primate Models of Parkinson’s Disease and Multiple System Atrophy](https://amydis.com/2021/06/28/amydis-awarded-3-million-nih-grant-to-explore-novel-alpha-synuclein-retinal-tracer-in-non-human-primate-models-of-parkinsons-disease-and-multiple-system-atrophy/) - Amydis Awarded $3 Million NIH Grant to Explore Novel Alpha Synuclein Retinal Tracer in Non-human Primate Models of Parkinson’s Disease and Multiple System Atrophy San Diego, October 11, 2021 (GLOBE NEWSWIRE) — Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye, today
- [Advances in Retinal Biomarkers and Retinal Tracers](https://amydis.com/2023/01/01/advances-in-retinal-biomarkers-and-retinal-tracers/) - Advances in Retinal Biomarkers and Retinal Tracers Investigational tracers could streamline diagnosis of retinal and systemic disease. Jan./Feb., 2023 (Retinal Physician Susan Worley, Contributing Writer) –During the past 2 decades, the pace of research devoted to the development of retinal biomarkers for a range of neurodegenerative diseases1-3 and neurologic disorders4 has increased dramatically. Because most neurodegenerative
- [Everything ALS Video Presentation: “The Amydis Eye Test to Detect ALS”](https://amydis.com/2023/03/22/the-amydis-eye-test-to-detect-als/) - Everything ALS Video Presentation: “The Amydis Eye Test to Detect ALS” Inside Amydis Strategy to Transform Neurodegenerative Disease Detection March 30, 2026 Amydis awarded $2.5M to develop diagnostic eye test for ALS March 16, 2026 Amydis receives phase 2 NIH grant award of $2.5 million to advance a novel approach to detect biomarker TDP-43 March
- [Translational Research, Leading the Way to Early Detection and Life-Saving Diagnoses](https://amydis.com/2023/09/01/translational-research-leading-the-way-to-early-detection-and-life-saving-diagnoses/) - Translational Research, Leading the Way to Early Detection and Life-Saving Diagnoses In their pursuit of improving lives and preserving vision, two Wills Eye faculty members are collaborating on several studies with colleagues in non-ophthalmic fields of inquiry. This multidisciplinary, team approach has proven pivotal.The translational work of Jose S. Pulido, MD, MS, MPH, MBA, the

## Pages

- [Homepage V3](https://amydis.com/) - Amydis is the leader in developing a new class of diagnostic compounds that enable digital detection and monitoring of human disease-related molecular biomarkers through standard ocular imaging cameras.
- [Contact Us](https://amydis.com/contact-us/) - Send Amydis a message or ask us a question today through our email form!
- [Media Page](https://amydis.com/media/) - Take a look at the different blogs and press releases written about Amydis and our Retinal Tracers.
- [Team](https://amydis.com/team/) - Meet the team that powers Amydis and all its innovations and brings extensive experience and expertise.
- [Philip Werthman](https://amydis.com/philip-werthman/) - Philip Werthman, MD, MMH Dr. Philip Werthman is a globally recognized microsurgeon, men’s health and longevity specialist, biotech investor, military historian, and philanthropist. He serves as Founder and President of Merkava Holdings, Chairman of Rithem Life Sciences, and formerly chaired the Scientific Advisory Board of GT Biopharma (NASDAQ: GTBP). He is an advisor to many
- [Christine Aylward](https://amydis.com/christine-aylward/) - CHRISTINE AYLWARD Christine Aylward founded Magnetic Ventures in 2018 and focuses on early stage investing at the intersection of life science and technology. She has worked at the forefront of healthcare innovation since the start of her career and has been in the venture capital business since 2011. Ms. Aylward started her career at Roche
- [Vicki P. Raeburn, Ph.D.](https://amydis.com/vicki-p-raeburn-ph-d/) - Vicki P. Raeburn, Ph.D. Chief Data Science Officer Vicki Raeburn has over 40 years of experience leading data and analytical operations for global companies. She has implemented data strategies, operations, and quality programs to deliver value-added analytical solutions for a variety of customer segments.Vicki has been responsible for data, information, and analysis at several information
- [Hidden Team](https://amydis.com/hidden-team/) - TEAM Our executive team is focused on operational excellence Stella Sarraf, PhD Chief Executive Officer BIO Ali Tafreshi Chief Technology Advisor BIO Kerri Nelson Chief Operating Officer BIO Vicki P. Raeburn, Ph.D. Chief Data Science Officer BIO Alex Huang, MD, PhD Chief Medical Advisor BIO Our Advisory Board brings extensive experience and expertise Robert Weinreb,
- [SriniVas R. Sadda](https://amydis.com/srinivas-r-sadda/) - SRINIVAS R. SADDA, MD Dr. SriniVas R. Sadda, MD, is the Director of Artificial Intelligence & Imaging Research at the Doheny Eye Institute and Professor of Ophthalmology at the University of California, Los Angeles (UCLA) Geffen School of Medicine. He received his MD from Johns Hopkins University, where he also completed ophthalmology residency and neuro-ophthalmology
- [About Us](https://amydis.com/about-us/) - Amydis is developing small molecule ocular tracers, which enable direct visualization of CNS disease-related molecular biomarkers in the eye. Amydis aims to be a global leader in developing ocular tracers for degenerative and systemic diseases
- [Technology](https://amydis.com/technology/) - Technology Amydis detects molecular biomarkers in the eye Accessible, affordable, adoptable, designed to fit the clinical workflow Amydis patent-protected eye tracer formulated to address different markets. Use imaging technologies and workflows already established in eye care practices. Molecular biomarker images captured during office visit to power AI-based insights. Why the eye? The eye reveals pathologies
- [Privacy Notice](https://amydis.com/privacy-notice/) - Amydis Privacy Notice Last Updated: 07/25/2024Amydis, Inc. (“Amydis”, “we”, “us”, and/or “our”) is developing proprietary ocular tracers that enable identification of molecular biomarkers for diseases of the eye, heart and brain.This Privacy Notice describes how Amydis handles personal information that we collect from and about you when do any of the following:visit our main public
- [Jerre Stead](https://amydis.com/jerre-stead/) - JERRE STEAD Jerre Stead is founder and chairman of Stead Impact Ventures. He was Executive Chairman and Chief Executive Officer of Clarivate plc from June 2019 until his retirement in October 2022. Mr. Stead served as CEO of Churchill Capital Corp until its merger with Clarivate in May 2019. During his career, Mr. Stead has
- [Ali Tafreshi](https://amydis.com/ali-tafreshi/) - ALI TAFRESHI Chief Technology Advisor Ali Tafreshi has over 18 years of experience in the field of eye care, with an expansive range of clinical expertise including glaucoma, neuro-ophthalmic diseases and retinal conditions, and multiple roles in the eye care industry. Mr. Tafreshi spent 10 years at the Hamilton Glaucoma Research Center in San Diego
- [Kerri Nelson](https://amydis.com/kerri-nelson/) - KERRI NELSON Chief Operating Officer Kerri Nelson has spent the past 30 years in critical strategic and operational roles for three global, publically traded information companies (Dun & Bradstreet, IHS Markit, Clarivate). She held C-Level positions that included data strategy, product management, customer operations, acquisition integration and quote-to-cash. Most recently, she was the Chief Operations
- [Eric M. Reiman](https://amydis.com/eric-m-reiman/) - ERIC M. REIMAN, MD Dr. Reiman is Executive Director of Banner Alzheimer’s Institute, Chief Executive Officer of Banner Research, Professor of Psychiatry at the University of Arizona, University Professor of Neuroscience at Arizona State University, Senior Scientist at the Translational Genomics Research Institute, Director of the Arizona Alzheimer’s Consortium and NIH-sponsored Arizona Alzheimer’s Disease Research
- [Sole D Agostino](https://amydis.com/sole-d-agostino/) - SOLE D'AGOSTINO Chief Product Officer Soledad D’Agostino has 17 years of product experience in technology businesses, including leadership roles at Google, YouTube and Microsoft. Her deep understanding of user needs gained her top recognition at Alphabet, as well as a notable track record of global product success. Ms. D’Agostino has led, supervised and contributed to
- [Diseases](https://amydis.com/diseases/) - Amydis detects molecular biomarkers in the eye for diseases including Ophthalmic Diseases, Neurodegenerative Diseases, and Cardiological Diseases.
- [Mervyn Turner](https://amydis.com/mervyn-turner/) - MERVYN TURNER, PhD Dr. Mervyn Turner has nearly 35 years of experience in pharmaceutical drug discovery, research and development, licensing and business development, emerging markets strategy development and implementation. He currently operates his own consulting firm, MJ Turner Consulting, where he counsels biotech, pharma, venture capital and investment banking firms. Dr. Turner spent 27 years
- [Robert Zamboni](https://amydis.com/robert-zamboni/) - Robert Zamboni, PhD Dr. Robert Zamboni has more than 40 years of drug discovery experience and is the recipient of multiple awards and prizes, including the Lionel Boulet Prize in 1999 (Prix du Québec), the Prix Galien in 2000 and the Heroes of Chemistry award in 2003. Dr. Zamboni first joined Merck Frosst-Canada as a
- [Irene Litvan](https://amydis.com/irene-litvan/) - IRENE LITVAN, MD Dr. Irene Litvan is a professor of neurology, the Tasch Endowed Chair of Parkinson’s Disease Research, and director of the Movement Disorder Center at the University of California, San Diego. She has over 25 years of experience in epidemiology, neurological disorders (particularly Parkinson’s disorders), psychiatry, and cognitive neuroscience. Dr. Litvan has published
- [Jose Pulido](https://amydis.com/jose-pulido/) - JOSE PULIDO, MD, MS, MBA, MPH Dr. Jose Pulido is a board-certified ophthalmologist with an extensive research portfolio that has focused on vitreoretinal infectious and inflammatory diseases, retinal degeneration, stem cells, checkpoint inhibitors, and immunotherapies. He has published nearly 350 peer-reviewed ophthalmic papers, and numerous books, book chapters, and editorials. Dr. Pulido assumed his role
- [Alex Huang](https://amydis.com/alex-huang/) - ALEX HUANG, MD, PhD Chief Medical Advisor Dr. Alex A. Huang, MD, is a board-certified ophthalmologist at the Shiley Eye Institute at UC San Diego Health. He is a glaucoma specialist, advanced cataract surgeon and clinician-scientist who performs all current and minimally invasive glaucoma surgical procedures. Dr. Huang also serves as the Alfred Vogt Chair
- [ALFREDO SADUN](https://amydis.com/alfredo-sadun/) - ALFREDO SADUN, MD, PhD Dr. Alfredo Sadun holds the Flora L. Thornton Endowed Chair at Doheny Eye Centers-UCLA and is Vice Chair of Ophthalmology at UCLA. Dr. Sadun graduated from MIT in 1972, completed his PhD and MD, and then a residency in Ophthalmology at Harvard Medical School followed by a fellowship in Neuro-Ophthalmology. He
- [David S. Boyer](https://amydis.com/david-s-boyer/) - DAVID S. BOYER, MD Dr. David Boyer is a world-renowned clinician, surgeon, and educator. In 1982, Dr. Boyer helped co-pioneer the formation of the Retina-Vitreous Associates Medical Group in Los Angeles. Now, with nine other doctors and six other locations in the Southern California area, Retina Vitreous Associates Medical Group has become a nationally recognized
- [Robert Weinreb](https://amydis.com/robert-weinreb/) - ROBERT WEINREB, MD Chair of Scientific Advisory Board Dr. Robert N. Weinreb, M.D. is the Chair and Distinguished Professor of Ophthalmology at the University of California, San Diego as well as Director of the Shiley Eye Institute and the Director of the Hamilton Glaucoma Center. He also holds the Morris Gleich MD Chair of Glaucoma
- [Steven D. Schwartz](https://amydis.com/steven-d-schwartz/) - STEVEN D. SCHWARTZ, MD Dr. Steven Schwartz currently serves as Ahmanson Professor of Ophthalmology, Professor-in-Residence of Ophthalmology, Chief of Retina Division, Director for Diabetic Eye Disease and Retinal Vascular Center, and Director of the Ophthalmic Photography Clinical Laboratory for Jules Stein Eye Institute at the University of California, Los Angeles (UCLA). He received his medical
- [Stella Sarraf, PhD](https://amydis.com/stella-sarraf/) - STELLA SARRAF, PhD Chief Executive Officer Dr. Sarraf founded Amydis in 2013 after seeing a clinical need for a novel technology to enable early detection of neurodegenerative diseases. She brings a blend of large pharmaceutical operational expertise, venture investment background and entrepreneurship to Amydis. Dr. Sarraf is viewed as a visionary with a deep understanding
- [A. James Khodabakhsh](https://amydis.com/a-james-khodabakhsh/) - A. JAMES KHODABAKHSH, MD Dr. A. James Khodabakhsh, MD is the Chief of Ophthalmology at Cedars-Sinai and Managing Partner of Specialty Surgical Center of Beverly Hills. Dr. Khodabakhsh is one of Beverly Hills’ premier anterior segment surgeons and became a Clinical Assistant Professor of Ophthalmology. He is board certified in ophthalmology and specializes in small
- [Jeffrey Kordower](https://amydis.com/jeffrey-kordower/) - JEFFREY KORDOWER, PhD Dr. Jeffrey Kordower is the founding director of the ASU-Banner Neurodegenerative Disease Research Center and endowed chair as The Charlene and J. Orin Edson Distinguished Director at the Biodesign Institute at Arizona State University. Dr. Kordower has for decades been an international leader in the field of Parkinson’s disease and related disorders.
- [Raymond Scott Turner](https://amydis.com/raymond-scott-turner/) - RAYMOND SCOTT TURNER, MD, PhD Dr. Raymond Turner is Professor of Neurology and Director of the Memory Disorders program at MedStar Georgetown University Medical Center. Before his recruitment to Georgetown in 2008, he was Chief of the Neurology service at the VA Ann Arbor Healthcare System and Associate Professor and Associate Chair in the Department
- [Sample Page](https://amydis.com/sample-page/) - This is an example page. It's different from a blog post because it will stay in one place and will show up in your site navigation (in most themes). Most people start with an About page that introduces them to potential site visitors. It might say something like this: Hi there! I'm a bike messenger

## Categories

- [Uncategorized](https://amydis.com/category/uncategorized/)
- [Press Release](https://amydis.com/category/press-release/)
- [News](https://amydis.com/category/news/)